Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 236

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Current status of autologous stem cell transplantation for multiple myeloma

Open access
Al Hamed, Rama, Bazarbachi, Abdul Hamid, Malard, Florent, Harousseau, Jean-Luc, Mohty, Mohamad · 2019 · Blood Cancer Journal

Abstract

More than 30 years after its introduction, autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple myeloma. Not only did the arrival of novel agents such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PI) and monoclonal antibodies not replace ASCT, instead they solidified its central role as standard of care. Novel agent use is now inarguably essential in induction, maintenance, and possibly consolidation. In light of these new advancements, new challenges arise in deciding on optimal practice. Who is most suited to undergo ASCT? Is there an age threshold that should not be surpassed? Should transplantation be embarked on early or is it reasonable to delay it? What are the optimal induction, consolidation, and maintenance therapies? What is the role of tandem transplantation in the era of novel agents and where do patient-specific cytogenetics come into the equation when deciding on treatment? These are some of the questions addressed in this review which we will attempt to answer with the latest currently available data.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41408-019-0205-9

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 93

  1. Harousseau, J. L. & Moreau, P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 360, 2645–2654 (2009). · DOI · Paper page
  2. McElwain, T. J. & Powles, R. L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2, 822–824 (1983). · DOI · Paper page
  3. Barlogie, B., Hall, R., Zander, A., Dicke, K. & Alexanian, R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67, 1298–1301 (1986). · DOI · Paper page
  4. Barlogie, B. et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70, 869–872 (1987). · DOI · Paper page
  5. Mohty, M. & Harousseau, J. L. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica 99, 408–416 (2014). · DOI
  6. Attal, M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335, 91–97 (1996). · DOI · Paper page
  7. Koreth, J. et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol. Blood Marrow Transplant. 13, 183–196 (2007). · DOI · Paper page
  8. Barlogie, B., van Rhee, F., Shaughnessy, J. D. Jr, Anaissie, E. & Crowley, J. Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. Leukemia 22, 1633–1636 (2008). · DOI
  9. Paiva, B. et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J. Clin. Oncol. 29, 1627–1633 (2011). · DOI · Paper page
  10. Ladetto, M. et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J. Clin. Oncol. 28, 2077–2084 (2010). · DOI · Paper page
  11. Cavo, M. et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376, 2075–2085 (2010). · DOI · Paper page
  12. Moreau, P., Avet-Loiseau, H., Harousseau, J. L. & Attal, M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J. Clin. Oncol. 29, 1898–1906 (2011). · DOI
  13. Facon, T. et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370, 1209–1218 (2007). · DOI · Paper page
  14. Badros, A. et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br. J. Haematol. 114, 600–607 (2001). · DOI · Paper page
  15. Judith Neukirchen, P. A. et al. Favourable outcome of elderly patients with multiple myeloma treated with tandem melphalan 100 high-dose therapy, autologous stem cell transplantation and novel agents—a single center experience. Blood 128, 3460 (2016). · doi:10.1182/blood.v128.22.3460.3460
  16. Palumbo, A. et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 94, 1248–1253 (1999). · DOI · Paper page
  17. Gay, F. et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood 122, 1376–1383 (2013). · DOI
  18. Straka, C. et al. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica 101, 1398–1406 (2016). · DOI
  19. Badros, A. et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br. J. Haematol. 114, 822–829 (2001). · DOI · Paper page
  20. Tosi, P. et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 14, 1310–1313 (2000). · doi:10.1038/sj.leu.2401819
  21. Waszczuk-Gajda, A. et al. Autologous peripheral blood stem cell transplantation in dialysis-dependent multiple myeloma patients—DAUTOS Study of the Polish Myeloma Study Group. Eur. J. Haematol. 101, 475–485 (2018). · doi:10.1111/ejh.13101
  22. Mahindra, A. et al. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant. 52, 1616–1622 (2017). · DOI
  23. Lokhorst, H. M. et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115, 1113–1120 (2010). · DOI · Paper page
  24. Harousseau, J. L. et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J. Clin. Oncol. 28, 4621–4629 (2010). · DOI · Paper page
  25. Morgan, G. J. et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 97, 442–450 (2012). · DOI · Paper page
  26. Sonneveld, P. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J. Clin. Oncol. 30, 2946–2955 (2012). · DOI · Paper page
  27. Moreau, P. et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118, 5752–5758 (2011). quiz 982. · DOI · Paper page
  28. Rosinol, L. et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120, 1589–1596 (2012). · DOI · Paper page
  29. Moreau, P. et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 127, 2569–2574 (2016). · DOI · Paper page
  30. Avet-Loiseau, H. et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 28, 4630–4634 (2010). · DOI · Paper page
  31. Sonneveld, P. et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J. Clin. Oncol. 31, 3279–3287 (2013). · DOI · Paper page
  32. Roussel, M. et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J. Clin. Oncol. 32, 2712–2717 (2014). · DOI · Paper page
  33. Rosinol, L. et al. Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) as induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a prospective phase III Pethema/GEM Trial. Blood 130(Suppl 1), 2017 (2017).
  34. Costello, C. An update on the role of daratumumab in the treatment of multiple myeloma. Ther. Adv. Hematol. 8, 28–37 (2017). · DOI
  35. Voorhees, P. M. et al. Interim safety analysis of a phase 2 randomized study of Daratumumab (Dara), Lenalidomide (R), Bortezomib (V), and Dexamethasone (d; Dara-RVd) vs. RVd in patients (Pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT). Blood 130(Suppl 1), 1879 (2017). · DOI
  36. Voorhees, P. M. et al. Efficacy and updated safety analysis of a safety run-in cohort from Griffin, a phase 2 randomized study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) vs. Vrd in patients (Pts) with newly diagnosed (ND) multiple myeloma (MM) eligible for high‐dose therapy (HDT) and autologous stem cell transplantation (ASCT). Blood 132(Suppl 1), 151 (2018). · DOI
  37. Yimer, H. et al. Lyra: a phase 2 study of Daratumumab (Dara) plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in newly diagnosed and relapsed patients (Pts) with multiple myeloma (MM). Blood, 132(Suppl 1), 152 (2018). · doi:10.1182/blood-2018-152
  38. Andrzej, J. et al. Daratumumab (DARA) in combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study. J. Clin. Oncol. 35, 8000–8000 (2017). · DOI
  39. Cavo, M. et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117, 6063–6073 (2011). · DOI · Paper page
  40. Moreau, P., Attal, M. & Facon, T. Frontline therapy of multiple myeloma. Blood 125, 3076–3084 (2015). · DOI · Paper page
  41. Anderson, K. C. et al. Multiple myeloma, Version 2.2016: clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 13, 1398–1435 (2015). · DOI
  42. Gertz, M. A. & Dingli, D. How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood 124, 882–890 (2014). · DOI
  43. Moreau, P. et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 117, 3041–3044 (2011). · DOI
  44. Binder, M. et al. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. Am. J. Hematol. 90, 888–891 (2015). · DOI
  45. Ludwig, H. et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J. Clin. Oncol. 31, 247–255 (2013). · DOI
  46. Sonneveld, P. et al. Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood 125, 449–456 (2015). · DOI
  47. Jakubowiak, A. J. et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120, 1801–1809 (2012). · DOI · Paper page
  48. Mohty, M. & Ho, A. D. In and out of the niche: perspectives in mobilization of hematopoietic stem cells. Exp. Hematol. 39, 723–729 (2011). · DOI
  49. Mohty, M. et al. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 25, 1–6 (2011). · DOI
  50. Bensinger, W., DiPersio, J. F. & McCarty, J. M. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 43, 181–195 (2009). · DOI · Paper page
  51. Larsen, S. R., Chng, K., Battah, F., Martiniello-Wilks, R. & Rasko, J. E. Improved granulocyte colony-stimulating factor mobilization of hemopoietic progenitors using cytokine combinations in primates. Stem Cells 26, 2974–2980 (2008). · DOI
  52. Sheppard, D., Bredeson, C., Allan, D. & Tay, J. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol. Blood Marrow Transplant. 18, 1191–1203 (2012). · DOI
  53. Desikan, K. R. et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J. Clin. Oncol. 16, 1547–1553 (1998). · DOI
  54. Russell, N. et al. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica 98, 172–178 (2013). · doi:10.3324/haematol.2012.071456
  55. de Mel, S. et al. Vinorelbine-Cyclophosphamide compared to Cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma. Hematol. Oncol. Stem Cell Ther. 11, 225–232 (2018). · doi:10.1016/j.hemonc.2018.04.001
  56. Gettys, S. C. et al. Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. Eur. J. Haematol. 98, 388–392 (2017). · doi:10.1111/ejh.12843
  57. Czerw, T. et al. Increased efficacy of stem cell chemo-mobilization with intermediate-dose cytarabine plus G-CSF compared with G-CSF alone in patients with multiple myeloma: results of a randomized trial. Biol. Blood Marrow Transplant. https://doi.org/10.1016/j.bbmt.2018.09.023 (2018). · DOI
  58. Mazumder, A. et al. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 22, 1280–1281 (2008). author reply1–2. · DOI · Paper page
  59. Li, S., Fu, J., Ma, H., Mapara, M. Y. & Lentzsch, S. Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization. Leukemia 27, 1407–1411 (2013). · DOI
  60. Silvennoinen, R. et al. A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. Bone Marrow Transplant. 51, 372–376 (2016). · DOI
  61. Malard, F. et al. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol. Blood. Marrow Transplant. 18, 314–317 (2012). · DOI
  62. Wang, G. et al. Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: a cohort study. Medicine (Baltimore) 96, e9302 (2017). · DOI
  63. Lahuerta, J. J. et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 95, 1913–1920 (2010). · DOI
  64. Blanes, M. et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol. Blood Marrow Transplant. 19, 69–74 (2013). · DOI
  65. Moreau, P. et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 23, 1003–1006 (1999). · doi:10.1038/sj.bmt.1701763
  66. Bensinger, W. I. et al. A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant. 51, 67–71 (2016). · DOI
  67. Hari, P. et al. Final outcomes of escalated melphalan 280 mg/m(2) with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. Bone Marrow Transplant. 54, 293–299 (2019). · DOI
  68. Roussel, M. et al. Bortezomib and high-dose Melphalan vs. high-dose melphalan as conditioning regimen before autologous stem cell transplantation in de novo multiple myeloma patients: a phase 3 study of the Intergroupe Francophone Du Myelome (IFM 2014-02). Blood 130(Suppl 1), 398 (2017).
  69. Farag, S. et al. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. Hematol. Oncol. 36, 671–678 (2018). · DOI
  70. Martino, M. et al. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Bone Marrow Transplant. 51, 1197–1203 (2016). · DOI
  71. Stadtmauer, E. A. et al. Comparison of autologous hematopoietic cell transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem Autohct with Len maintenance (TAM) and Autohct with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702-StaMINA Trial). Blood 128, LBA-1 (2016). · DOI
  72. Paiva, B. et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 119, 687–691 (2012). · DOI · Paper page
  73. Morgan, G. J. et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119, 7–15 (2012). · DOI · Paper page
  74. Ludwig, H. et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 119, 3003–3015 (2012). · DOI · Paper page
  75. Stewart, A. K. et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 121, 1517–1523 (2013). · DOI
  76. Spencer, A. et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J. Clin. Oncol. 27, 1788–1793 (2009). · DOI · Paper page
  77. Jackson, G. et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the Myeloma XI Trial. Blood 130(Suppl 1), 436 (2017).
  78. Patel, K. K. et al. Update on a phase II study of Ixazomib with Lenalidomide as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma. Blood 130(Suppl 1), 437 (2017).
  79. Dimopoulos, M. A. et al. Maintenance therapy with the oral proteasome inhibitor (PI) Ixazomib significantly prolongs progression-free survival (PFS) following autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. Blood, 132(Suppl 1), 301 (2018). · doi:10.1182/blood-2018-99-112079
  80. Barlogie, B. et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89, 789–793 (1997). · DOI · Paper page
  81. Barlogie, B. et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br. J. Haematol. 138, 176–185 (2007). · DOI · Paper page
  82. Mai, E. K. et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br. J. Haematol. 173, 731–741 (2016). · DOI
  83. Cavo, M. et al. Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial). Blood 128, 991 (2016). · DOI
  84. Gay, F. et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 16, 1617–1629 (2015). · DOI · Paper page
  85. Richardson, P. G., Laubach, J. P., Munshi, N. C. & Anderson, K. C. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematol Am. Soc. Hematol. Educ. Program 2014, 255–261 (2014). · DOI
  86. Giralt, S. et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol. Blood. Marrow Transplant. 21, 2039–2051 (2015). · DOI · Paper page
  87. Cook, G. et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 3, e340–e351 (2016). · DOI
  88. Atanackovic, D. & Schilling, G. Second autologous transplant as salvage therapy in multiple myeloma. Br. J. Haematol. 163, 565–572 (2013). · DOI
  89. Mateos, M. V. et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for untreated myeloma. N. Engl. J. Med. 378, 518–528 (2018). · DOI · Paper page
  90. Thierry Facon, S. K. K. et al. Phase 3 randomized study of Daratumumab plus Lenalidomide and Dexamethasone (D-Rd) versus Lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA). In ASH Annual Meeting Abstracts, Late-Breaking Abstracts Session, LBA-2 (2018). · DOI · Paper page
  91. Miller, K. C. et al. Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 54, 587–594 (2019). · DOI
  92. Paiva, B. P. N. et al. Impact of next-generation flow (NGF) minimal residual disease (MRD) monitoring in multiple myeloma (MM): results from the Pethema/GEM2012 Trial. Blood, ASH Annual Meeting Abstracts, Vol. 130, Suppl.1, 905 (2017). · doi:10.1182/blood.v130.suppl_1.905.905
  93. Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132, 2456–2464 (2018). · DOI · Paper page

Cited by

See all 236

Metadata

Authors
Al Hamed, R., Bazarbachi, A. H., Malard, F., Harousseau, J.-L., & Mohty, M.
Venue
Blood Cancer Journal
Published
2019-04-08
Volume
9
Issue
4
Pages
44-44
ISSN
2044-5385 (ISSN-L)
OpenAlex
W2936045790
Cited by
236
References
12
FWCI
18.43
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current status of autologous stem cell transplantation for multiple myeloma. https://app.cochat.ai/papers/10.1038/s41408-019-0205-9
The paper
Al Hamed, R., Bazarbachi, A. H., Malard, F., Harousseau, J.-L., & Mohty, M. (2019). Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal. https://doi.org/10.1038/s41408-019-0205-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.